To Investigate the Efficacy and Mechanism of ZBP Powder Product in the Treatment of Osteopenia in Patients With Pain.

Osteopenia Clinical Trial

Official title:

To Investigate the Efficacy and Mechanism of ZBP Powder Product in the Treatment of Osteopenia in Patients With Pain.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03245710
• Other study ID #: N201602096
• Status: Recruiting
• Phase: N/A
• Start date: February 8, 2017
• Est. completion date: March 7, 2021

Study information

• Verified date: April 2020
• Source: Taipei Medical University WanFang Hospital
• Contact: Chung-Yu Huang, MD
• Phone: +886-29307930
• Email: hcy[@]tmu.edu.tw
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study investigates the efficacy and mechanism of traditional Chinese medicine formula power product in the treatment of osteopenia in patients with pain. Half of participants will receive Chinese medicine formula power product, while the other half will receive a placebo.

Description:

Osteoporosis is a major public health problem, resulting in potentially pain and increasing risk of fracture. Treatment of osteoporosis consists of pharmacotherapy, lifestyle measures, dietary changes, mineral supplementation. Traditional Chinese medicine is a major component of health care in Taiwan and provides one treatment alternative for osteoporosis.

Investigators investigate the efficacy and mechanism of traditional Chinese medicine formula powder product in the treatment of osteopenia patients with pain.This trial is a 12 weeks' randomized, placebo-controlled study. The study was approved by the Wan Fang hospital, and signed informed consent was obtained from each participant. 80 Osteopenia participants with pain were enrolled in this study. There were 80 participants aged 50 years or older included. Before random assignment to treatment, participants were at least moderate pain during 2 weeks as identified by visual analogue scale (VAS) for more than 4. Bone mineral density (BMD) of all participants was -2.5 or below without diabetes, hyperthyroidism, hypoparathyroidism, liver or kidney function disorder, ovariectomy, rheumatoid arthritis, bone cancer, ever used hormone agent within 6 months before assignment to treatment, ever used steroids more than 3 week before assignment to treatment, Primary outcome measures were the change of VAS scale, Oswestry Disability Index and WHOQOL-BREF Taiwan at week 1 and 12. Secondary outcome was the genetic loci associated with a susceptibility to osteoprosis treated by traditional Chinese medicine formula powder product.

Result : To provide evidence of the efficacy and mechanisms of ZBP powder product in the treatment of osteoporosis patients with pain.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: March 7, 2021
• Est. primary completion date: May 7, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

1. aged 50 years or older.

2. VAS score?4.0 in a week.

3. bone mineral density (BMD) of all participants was -2.5 or below.

Exclusion Criteria:

1. diabetes.

2. thyroidism function disorder.

3. parathyroidism function disorder.

4. liver or kidney function disorder.

5. ovariectomy

6. rheumatoid arthritis.

7. bone cancer.

8. ever used hormone agent within 6 months before assignment to treatment.

9. ever used steroids more than 3 months before assignment to treatment.

10. ever used analgesics, excepted acetaminophen, more than 1 week before assignment to treatment.

Related Conditions & MeSH terms

• Bone Diseases, Metabolic
• Osteopenia

Intervention

Other:
• Placebos
starch

Dietary Supplement:
• Zhibai Dihuang powder
the Traditional Chinese Medicine Formula Powder Product

Locations

Country	Name	City	State
Taiwan	WanFangH	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
Taipei Medical University WanFang Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pain on the visual-analogue scales (VAS) for back and legs.	A VAS is a 100-mm-long horizontal line that is anchored by word descriptors at each end (no pain and worst pain possible). The patient selects the point on the line that best represents his or her perception of their pain level.	baseline and week 12